Sarah Boyce - 27 Feb 2026 Form 4 Insider Report for Atrium Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: RNA on Nasdaq
Reported as of: 27 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 18:00:08 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Grajewski, Attorney-in-Fact

Key filing fact

Sarah Boyce filed Form 4 for Atrium Therapeutics, Inc. on 02 Mar 2026.

Key facts

This page summarizes Sarah Boyce's Form 4 filing for Atrium Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 18:00.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001629383 Primary reporting owner

Boyce Sarah

Relationship: Director
Address: C/O ATRIUM THERAPEUTICS, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO
Signature: /s/ Adam Grajewski, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $14.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.